Article

Peptide-Specific CARs Recognize WT1 Promiscuously Presented by Diverse HLA Class II Alleles

2025-07-04

Abstract excerpt

Chimeric antigen receptor (CAR) technology has revolutionized B-cell malignancy treatment by enabling T cells to effectively recognize and target cancer-specific surface antigens. However, CAR T cells show limited efficacy against other blood cancers and solid tumors due to challenges in identifying suitable surface targets. Here, we present a novel approach to CAR development, targeting the intracellular Wilms’ t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 33858d88-5415-54c6-a01f-dae7741942e4
DOI: 10.1101/2025.06.30.660492

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Peptide-Specific CARs Recognize WT1 Promiscuously Presented by Diverse HLA Class II AllelesDOI 10.1101/2025.06.30.660492Read

Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.Semantic proximity Read

Understanding CD8+ T‐cell responses toward the native and alternate HLA‐A∗02:01‐restricted WT1 epitopeSemantic proximity Read

In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity.Semantic proximity Read

CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell functionSemantic proximity Read

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevanceSemantic proximity Read

Baseline WT1-specific immunity and immune responses to WT1-targeted immunotherapy in pediatric patients with malignant solid tumors at high risk for relapse: results from a biomarker-driven multicenter translational phase II clinical trialSemantic proximity Read

Allogeneic HLA-A*02–Restricted WT1-Specific T Cells from Mismatched Donors Are Highly Reactive but Show Off-Target PromiscuitySemantic proximity Read

Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics.Semantic proximity Read

Targeting of intracellular oncoproteins with peptide-centric CARs.Semantic proximity Read

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemiasSemantic proximity Read

Multifaceted functions of the Wilms tumor 1 protein: From its expression in various malignancies to targeted therapySemantic proximity Read

Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.Semantic proximity Read